Siemens Healthineers Launches Enhanced Liver Fibrosis (ELF) Test in the U.S.

February 21, 2022

Labcorp completes acquisition of Personal Genome Diagnostics

BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 21, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of Personal Genome Diagnostics Inc. ( PGDx ), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.
February 9, 2022

Labcorp enters comprehensive, long-term laboratory relationship with Ascension

BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 9, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into agreements to create a comprehensive strategic relationship with Ascension, one of the nation’s leading Catholic and non-profit health systems. Through the expansive strategic collaboration, Labcorp will manage Ascension’s hospital-based laboratories in 10 states and purchase select assets of the health system’s outreach laboratory business. This long-term relationship will expand Labcorp’s clinical laboratory services in several states across the country while creating opportunities to enhance care across all clinical areas.

Labcorp Enters Comprehensive, Long-Term Laboratory Relationship With Ascension

Labcorp Opens New Laboratory in South Bend, Expanding Services and Access in the Midwest